Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: Its association with clinicopathologic features

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6177-6185

  Shibata, Tatsuhiro ^a   Uryu, Satomi ^a   Kokubu, Akiko ^a   Hosoda, Fumie ^a   Ohki, Misao ^a   Sakiyama, Tokuki ^a   Matsuno, Yoshihiro ^b   Tsuchiya, Ryosuke ^b   Kanai, Yae ^a   Kondo, Tadashi ^a   Imoto, Issei ^c,d   Inazawa, Johji ^c,d   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER GENETICS; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 17Q; CHROMOSOME 7P; CHROMOSOME 8P; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME NUMBER; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENDER; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HIGH THROUGHPUT SCREENING; HOMOZYGOUS DELETION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SUPERVISED CLUSTERING ANALYSIS; UNSUPERVISED HIERARCHICAL CLUSTERING ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MUTATION; NUCLEIC ACID HYBRIDIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 24344435084     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0293     Document Type: Article

References (49)

1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World Health Organization international histological classification of tumors. New York: Springer-Verlag; 1999. p. 5-26.
2. Osada H, Takahashi T. Oncogene 2002;21:7421-34.
3. Sekido Y, Fong KM, Minna JD. Annu Rev Med 2003; 54:73-87.
4. Sanchez-Cepedes M. Lung Cancer 2003;40:111-21.
5. Balsara BR, Testa JR. Oncogene 2002;21:6877-83.
6. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Cancer Res 2002;62:7001-3.
7. Stephens P, Hunter C, Bignell G, et al. Nature 2004; 431:525-6.
8. Lynch TJ, Bell DW, Sordella R, et al. N Engl J Med 2004;350:2129-39.
9. Paez JG, Janne PA, Lee JC, et al. Science 2004;304: 1497-500.
10. Pao W, Miller V, Zakowski M, et al. Proc Natl Acad Sci U S A 2004;101:13306-11.
11. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinoma by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98: 13790-5.
12. Garber EM, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad USA 2001;98: 13784-9.
13. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
14. Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol 2004;31:4-19.
15. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2: 561-6.
16. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004;64:3780-9.
17. Risques RA, Moreno V, Ribas M, Marcuello E, Capella G, Peinado MA. Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. Cancer Res 2003;63:7206-14.
18. Nakao K, Mehta KR, Fridlyand J, et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 2004;25:1345-57.
19. Aguirre AJ, Brennan C, Bailey G, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 2004;101: 9067-72.
20. Sonoda I, Imoto I, Inoue J, et al. Frequent silencing of low density lipoprotein receptor - related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res 2004;64:3741-7.
21. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274: 998-1001.
22. Tanabe C, Aoyagi K, Sakiyama T, et al. Evaluation of a whole-genome amplification method based on adaptor-ligation PCR of randomly sheared genomic DNA. Genes Chromosomes Cancer 2003; 38:168-76.
23. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH) - arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95:559-63.
24. Katoh H, Shibata T, Kokubu A, et al. Genetic profile of hepatocellular carcinoma revealed by array - based comparative genomic hybridization: Identification of genetic indicators to predict patient outcome. J Hepatol. In press 2005.
25. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation -dependent probe amplification. Nucleic Acids Res 2002;30: 57-62.
26. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004;40:609-17.
27. Seike M, Kondo T, Fujii K, et al. Proteomic signature of human cancer cells. Proteomics 2004;4:2776-88.
28. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999;125:61-70.
29. Pellegrini C, Falleni M, Marchetti A, et al. HER-2/ Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription - PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003;9: 3645-52.
30. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non - small cell lung cancer, and loci clustering. Cancer Res 2000;60: 4894-906.
31. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
32. Tokumo M,Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in nonsmall cell lung cancers. Clin Cancer Res 2005;11:1167-73.
33. Shigematsu H, Takahashi T Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-6.
34. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
35. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in chilhood hapatocellular carcinomas. Cancer Res 1999;59:307-10.
36. Ma PC, Kijima T, Maulik G, et al. c - Met mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81.
37. Dang TP, Gazdar AF, Virmani AK, et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 2000;92: 1355-7.
38. Forgacs E, Wren JD, Kamibayashi C, et al. Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. Oncogene 2001;20:1005-9.
39. Eguchi K, Kanai Y, Kobayashi K, Hirohashi S. DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. Cancer Res 1997;57:4913-5.
40. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
41. Yatabe Y, Koga T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 2004 Jun;203:645-52.
42. Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T. K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol Rep 2001;8:889-92.
43. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
44. Webb CP, Taylor GA, Jeffers M, et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 1998 Oct 22;17:2019-25.
45. Purge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasi through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA 2001;98:10722-7.
46. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and it's therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65:1479-88.
47. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9.
48. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and it's microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73.
49. Lynch TJ, Adjei AA, Bunn PA Jr, et al. Novel against in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004;10:4199-204.